• Invitrogen Corp., of Carlsbad, Calif., completed the financing related to its proposed acquisition of Foster City, Calif.-based Applied Biosystems Inc. reported in June, and said pricing for the $2.7 billion financing was in line with expected terms. The transaction, valued at about $6.7 billion, is expected to close in November. (See BioWorld Today, June 13, 2008.)

• ISTA Pharmaceuticals Inc., of Irvine, Calif., is securing access to $65 million in a credit facility agreement with long-term shareholders Deerfield Management, Sprout and Sanderling Ventures. ISTA has drawn $40 million and called its convertible debt for par. It will be able to draw up to an additional $25 million any time over the next 12 months. The company is advancing its pipeline products, including a Phase III-stage program with Xibrom (bromfenac ophthalmic solution) for pain and inflammation in cataract surgery and an expected new drug application for Bepreve expected by the end of this year. RBC Capital Markets acted as exclusive placement agent. Shares of ISTA (NASDAQ:ISTA) closed at $1.57 Friday, up 16 cents.

• MonoSol Rx, of Warren, N.J., closed a private equity round of $20 million, including the conversion of $10 million of a bridge loan debt funded in November 2007. The round was led by Ed Bass Group, of Fort Worth, Texas, with participation from the Halifax Group and CNF Investments. Funds will be used for general corporate purposes, capital equipment investments and to advance the company's research and development programs. MonoSol Rx develops PharmFilm, a thin film drug delivery technology.

• Novagali Pharma SA, of Evry, France, said it secured €15 million (US$21.9 million) in a financing round involving existing company investors. Funds will be used to develop the company's pipeline, including the commercialization in France and overseas of Cationorm in dry eye symptoms and the development of additional products: Vekacia in vernal keratoconjunctivitis, Cyclokat in dry eye, Nova21027 in glaucoma and Cortiject in diabetic macular edema.